Blood pressure–lowering therapy and treatment targets should be individualized in patients with frailty, a high risk of falls, very limited life expectancy, or symptomatic postural hypotension.
Therapies with strong evidence for delaying chronic kidney disease (CKD) progression include renin–angiotensin system inhibitors (RASi) and sodium–glucose cotransporter 2 inhibitors (SGLT2i). In patients with CKD and heart failure, SGLT2i provide benefits regardless of albuminuria status.
A modest initial decline in estimated glomerular filtration rate (eGFR) is expected following the initiation of hemodynamically active agents such as RASi and SGLT2i. However, a reduction in eGFR of ≥30% from baseline exceeds anticipated variability and should prompt further evaluation.
CKD is not a contraindication to invasive management strategies in patients with acute or unstable cardiac conditions. Similarly, imaging studies are not absolutely contraindicated in patients with CKD; the decision should be based on a careful assessment of individual risks and benefits.
